earticle

영어

The ability to generate patient’s induced pluripotent stem cells (iPSCs) could provide tremendous promises for regenerative medicine. It has reported that choice of reprogramming tools is essential for the safety and the increasing efficiency of reprogramming process and transduction. Non-integrating techniques as like mRNA based reprogramming protocols are available for the production of genetically stable iPSCs while avoiding the risks of genomic integration. In this study, to derive brain cancer patient’s iPSCs by mRNA’s reprogramming, we obtained patient’s somatic tissues at brain tumor surgery that informed consent obtained according to institutionally- approved protocols. Patient's primary somatic cells were isolated, and they used as the cell source for iPSCs generation under xeno-free conditions. Reprogramming produced by non-integration methods utilized the combination of reprogramming mRNAs (OSKMNL) with evasion mRNAs (EKB) (Stemgent) during four days. Reprogrammed cells showed the colonies like iPSCs after six days of transduction, and the colonies were expanded until pick-up at day 14. These colonies were stained for pluripotency-associated genes using TRA-1-60 and TRA-1-81 by immunocytochemistry. Established colonies were also expanded without feeder condition and stained with Alkaline Phosphatase. In the further study, generated patient's iPSCs will be required to investigate their availability of the clinical application under xeno-free conditions which could provide a path to GMP applicability that should facilitate the clinical implementation of patient- or disease-specific iPSCs therapies.